Ad5-nCoV (Convidicea)
phone-call sandwich
Ad5-nCoV (Convidicea)

Ad5-nCoV (Convidicea)

The Ad5-nCOV vaccine is best known as Convidecea. It uses the human adenovirus vector Ad5, which carries the coronavirus’ spike protein. The adenovirus serves as a “delivery method,” while the spike protein is the antigen to which an immune response is developed. Sputnik-V works in a similar fashion.
Ad5-nCoV

Ad5-nCoV

Vector vaccines like Sputnik-V and Convidecea extract the necessary gene from the genome of a whole virus (a piece of DNA or RNA) responsible for synthesizing the protein that helps the virus penetrate into human cells. If that protein is blocked, the virus cannot get inside the cells once inside the body and becomes inactive. Therefore, the main task for this technology is to find the right gene. Vector vaccines are distinguished by high immunogenicity: they form a fairly high concentration of protective antibodies. This is the most advanced vaccine technology available—pure genetic engineering.

Vaccine

Convidicea

Developer

CanSino Biologics Inc., China

Producer

CanSino Biologics Inc., China

Status

CanSino received authorization from the Russian Ministry of Health to participate in a widespread international Phase III trial to assess the effectiveness and immunogenicity of the Ad5-nCoV vaccine. This international study is being conducted in collaboration with Petrovaks, a Russian company. More than 40,000 volunteers took part in the clinical trial, including 8,000 Russian citizens. The first groups of volunteers have already been successfully vaccinated. They feel well, and nobody has experienced any serious negative side effects.

Key information

What’s in the vaccine?

The vaccine is based on a non-replicating viral vector using the recombinant Ad5 human adenovirus.



Vaccines developed and used in Russia